Earlier this week, argenx SE halted its Phase 3 UplighTED trials of subcutaneous efgartigimod for moderate to severe thyroid eye disease after an Independent Data Monitoring Committee recommended ...

The foundation for this progress is strengthened by intellectual property protection. Bionxt has received its first national patent for a fast-dissolving thin-film system. The protection, extending to ...

December has proven to be a period of significant acceleration for BioNxt Solutions. The development-stage biopharmaceutical firm is advancing on multiple st ...